Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Two Processes of GSK2340272A H1N1 Vaccine
NCT00992511Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- Nov 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of Q-Pan H1N1 in influenza (4 arms), sponsored by GSK. Primary endpoints: Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain at Day 21 and Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease at Day 21. Started Oct 2009; status: completed.
02
Drugs
Q-Pan H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00992511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992511.